Epithelial ovarian cancer (EOC) remains the deadliest form of gynecological cancers.
Optimal tumor debulking, no matter the primary or the interval, is the most important …

Primary chemotherapy treatment response monitoring in advanced epithelial ovarian cancer
(EOC) is currently based on CT-imaging and serum CA125 values. Serum HE4 profile …

Abstract Human epididymis protein 4 (HE4) is a novel tumour marker in epithelial ovarian
cancer (EOC). Data on its profile and predictive potential for subsequent outcome after …

Objective Human epididymis protein 4 (HE4) is a promising biomarker of epithelial ovarian
cancer (EOC). But its role in assessing the primary optimal debulking (OD) of EOC remains …

OBJECTIVES: Epithelial ovarian cancer (EOC) is the major cause of death due to
gynecological malignancies. The most important prognostic factors are residual tumor mass …

Objectives This study aimed to evaluate serum human epididymis protein 4 (HE4) changes
during neoadjuvant chemotherapy (NACT) to establish HE4 predebulking surgery cutoff …

Clinical utility of new biomarkers often requires the identification of their optimal threshold.
This external validation study was conducted to assess the performance of the preoperative …

Background Ovarian cancer (OC) is considered the most lethal gynecological cancer, of
which more than 65% cases are diagnosed in advanced stages, requiring platinum-based …

Background This study assessed the prognostic value of HE4 marker measurements at
various stages of first-line chemotherapy for ovarian cancer. Methods The study consisted of …

Purpose: Human Epididymis Protein 4 (HE4) is a novel promising serum biomarker of high
sensitivity and specificity for ovarian cancer (OC). We investigated the usefulness of HE4 in …